Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects Without or With Type 2 Diabetes
Conditions
Interventions
Gelesis200
Placebo
Locations
30
United States
Central Alabama Research
Birmingham, Alabama, United States
Meridien Research, Inc - Bradenton
Bradenton, Florida, United States
Baptist Diabetes Associates, P.A.
Miami, Florida, United States
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States
The Center for Pharmaceutical Research
Kansas City, Kansas, United States
Clinical Research Center of Nevada
Las Vegas, Nevada, United States
Start Date
February 22, 2017
Primary Completion Date
January 15, 2021
Completion Date
January 15, 2021
Last Updated
July 21, 2020
NCT07351045
NCT05398783
NCT07244458
NCT07508241
NCT07395687
NCT07311850
Lead Sponsor
Gelesis, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions